Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29876162 | 1.00 | KDM4E (0.31) | KDM4EMEN1ALDH1A1GAAMAPT | |
| SCHEMBL19104274 | 0.88 | KDM4E (0.30) | KDM4EMEN1ALDH1A1GAAMAPT | |
| SCHEMBL18153428 | 0.86 | MAPK14 (0.36) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL18128520 | 0.77 | ALDH1A1 (0.31) | ALDH1A1KMT2A | |
| SCHEMBL29654262 | 0.77 | ALDH1A1 (0.31) | ALDH1A1KMT2A | |
| SCHEMBL30101999 | 0.76 | — | — | |
| SCHEMBL22029169 | 0.76 | — | — | |
| SCHEMBL25805402 | 0.75 | MEN1 (0.37) | KDM4EMEN1ALDH1A1GAAMAPT | |
| SCHEMBL25382988 | 0.75 | KRAS (0.36) | KDM4EALDH1A1GAA | |
| SCHEMBL20571102 | 0.75 | MAP3K8 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50490-E1 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20230406849-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2023-12-21 | — | — | US | disclosed |
| CN-116867779-A | KRAS inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-4242207-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| EP-4242207-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023072188-A1 | KRAS G12D INHIBITORS AND USE THEREOF IN MEDICINE | 贝达药业股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-114920738-A | KRas inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022095960-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | 泰励生物科技（上海）有限公司 | 2022-05-12 | — | — | WO | disclosed |
| WO-2022095960-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | 泰励生物科技（上海）有限公司 | 2022-05-12 | — | — | WO | disclosed |
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190284144-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2019-09-19 | — | — | US | disclosed |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3280708-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20180015087-A1 | CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-01-18 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015087-A1 | CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | KDM4E 3815/4885MEN1 218/4885ALDH1A1 3952/4885 |
| US-20190284144-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | KDM4E 3345/4885MEN1 122/4885ALDH1A1 3753/4885 |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | KRAS, NRAS, HRAS | KDM4E 3345/4885MEN1 122/4885ALDH1A1 3753/4885 |
| US-20230406849-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | KRAS, NRAS, HRAS | KDM4E 3593/4885MEN1 226/4885ALDH1A1 2455/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | KDM4E 3345/4885MEN1 122/4885ALDH1A1 3753/4885 |
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | KRAS, NRAS, HRAS | KDM4E 3345/4885MEN1 122/4885ALDH1A1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.